OCT Announces 2nd Clinical Trial, Chill Brands Investor Calls For Director Ousting, & More From SEED
Oxford Cannabinoid Technologies Oxford Cannabinoid Technologies (OCT) has announced plans to launch a Phase 1 clinical trial into a
Oxford Cannabinoid Technologies Oxford Cannabinoid Technologies (OCT) has announced plans to launch a Phase 1 clinical trial into a
This week, British pharmaceutical cannabis firm Oxford Cannabinoid Technologies (OCT) announced that the ‘final dose’ in its crucial Phase I
OCTP, the pharmaceutical company developing prescription cannabinoid medicines, is formally expanding its research and development strategy into oncology having identified
Oxford Cannabinoid Technologies The London Stock Exchange listed pharmaceutical cannabis company announced yesterday that it has at last
OXFORD Cannabinoid Technologies Holdings plc (LSE: OCTP, OTCQB: OCTHF), the pharmaceutical company developing prescription cannabinoid medicines targeting the US$ multi-billion
We won’t spam you
© 2024 Prohibition Holdings Ltd. All Rights Reserved.
© 2023 Prohibition Holdings Ltd. All Rights Reserved.